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Abstract
Purpose To assess the impact on exposure time and outcome misclassifications, and consequent impact on exposure-outcome
associations from treatment episode construction. We investigated the dosage assumptions of 1 unit per day, and 1 DDD per day,
versus actual prescribed dosage under different handling of gaps and overlaps of prescriptions.
Methods Data onmirtazapine and citalopram exposure (years 2006–2014) from the Swedish Prescribed Drug register were used.
Via a within individuals design we compared method A, based on actual dosage, with methods B and C based on 1 unit of drug
per day and 1 DDD per day assumptions, respectively, including consideration of gaps and overlaps. Four outcomes were used,
hospitalizations and outpatient visits for all and for psychiatric causes.
Results Relative to method A, both alternative methods lead to misclassification of exposure time. With regard to outcome
misclassifications, method B overestimates the effect of the exposure on the outcome in 77% and 100% of exposure definition
comparisons for mirtazapine and citalopram respectively, while 23% of the comparisons for mirtazapine results in underestima-
tion of exposure-outcome associations. Conversely, treatment episodes based on DDD (method C) result in underestimation of
the exposure-outcome association in 100% and 87.5% of exposure definition comparisons for mirtazapine and citalopram
respectively, while 12.5% of the comparisons for citalopram results in overestimation of the exposure-outcome associations.
Conclusions The study provides results that have consistent clinical relevance. We have showed that a non-accurate construction
of exposure time may lead to errors on outcome detection during exposed time, and consequently affect conclusions on safety or
efficacy profile of a treatment.
Keywords Treatment episode . Defined daily dose . Gaps . Overlaps . Treatment duration . Pharmacoepidemiology
Introduction
In the analysis of observational data, the choice of the
method to construct treatment episodes is crucial to
avoid misclassification of exposure time and to reduce
the impact on the estimation of exposure-outcome as-
sociations, defined as any difference in the occurrence
of the outcome between groups of individuals that dif-
fer by exposure. In studies using individual level data
from prescription registers for evaluating the associa-
tion of a pharmacological treatment with an outcome
of interest, the treatment episode’s construction is
based on available data on dispensed quantity, dosage,
or duration of the treatment [1]. However, in many
prescription registers information about the actual pre-
scribed dosage or duration of exposure is not available
and the approximation of an individual’s treatment
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episode length is based on assumptions about the pre-
scribed dosage. Moreover, the use of prescription reg-
isters to construct treatment episodes is based on the
assumption that individuals will use the medication in-
cluded in the filled prescriptions.
A common assumption to approximate the actual pre-
scribed dosage is based on the defined daily dose
(DDD), a statistical measure introduced by the WHO
Collaborating Centre for Drugs Statistics Methodology.
Formally, “the DDD is the assumed average mainte-
nance dose per day for a drug used for its main indi-
cation in adults” [2]. Accordingly, the dosage is as-
sumed to be one DDD per day [3–6]. The use of the
average maintenance dosage to approximate an individ-
ual’s treatment episode duration may lead to differing
conclusions [7–10]. Another commonly used dosage as-
sumption is a fixed number of units of drug per day, as
for example one unit per day, essentially equating days
of supply per prescription fill to the number of pre-
scribed units (tablets/pills/capsules) [11, 12].
When constructing treatment episodes, in addition to
dosage assumptions, the presence of gaps and overlaps
among prescriptions should be carefully considered
[13, 14]. Overlaps refer to time spans under which a
patient has supplies from two or more prescriptions of
the same drug. Gaps refer to the temporal distance
between two prescriptions that is in excess of the days
of supply of the first prescription. In the presence of
multiple prescriptions, the treatment episode duration is
affected by the way prescription overlaps are handled
and by assumptions about allowable gaps.
In the current study, we seek to assess the impact
of the assumptions of one unit per day, and one DDD
per day, versus actual prescribed dosage, on treatment
episode durations, while at the same time we system-
atically vary the length of the allowable gaps between
prescriptions, and the approach for handling overlaps.
Resulting differences in treatment episode durations
constructed under different assumptions may contrib-
ute to misclassification of exposure time and affect
epidemiologic measures of association between expo-
sure and outcomes. The current study also assesses
the odds of observing the outcome of interest during
the exposed time under different assumptions for
treatment episode construction. The hypothesis behind
the current study is that the use of different dosage
assumptions results in different treatment episode du-
rations, and thereby potential over- or underestimation
of measures of rates of outcomes due to misclassifi-
cation of the exposure time. To illustrate, we use
mirtazapine and citalopram, two antidepressant medi-
cations commonly used to treat major depressive
disorders.
Methods
Data sources
This was a non-interventional observational study utilizing
population data from the Swedish Prescribed Drug Register
(PDR), the National Patient Register (NPR), and the Total
Population Register (TPR). Data sources are described in
Appendix A of the supplementary material.
Study population
All individuals in the PDR with at least one prescription for
mirtazapine or citalopram in tablet form from January 2006 to
July 2014 were included. Included individuals were required
to be new users, defined as no treatment with mirtazapine or
citalopram for at least 6 months prior to the first observed
prescription, and with available information on actual pre-
scribed dosage in unstructured free-text format (information
on medication dosages are included in Appendix A of the
supplementary material). Additionally, included individuals
had no record of migration registered in the TPR, and did
not have dispensing of pre-packed daily supplies of the drugs
of interest.
Text-mining algorithm for extraction of the actual
prescribed dosage
In the PDR, the amount of dispensed drug is available as
number of units of drug, unit strength and number of dis-
pensed DDDs. A semi-manual, iterative method was used to
ascertain the actual prescribed dosage for the particular drug
from available unstructured free-text format data.
Accordingly, a proportion of the dosage texts was read to
create a look-up table associating dose text and prescribed
dosage (numerical, number of units) of medication per day.
Text that did not contain any information on dosage or was
otherwise uninformative was omitted. The remaining pre-
scriptions were merged with the look-up table of the manually
extracted dosages. The result was manually proofread [15].
Information on dosages for mirtazapine and citalopram are
reported in Appendix A.
Treatment episode construction
When constructing treatment episodes using register data, the
main source is often an administrative record of prescription
fills, which allows to aggregate the days of supply over all
eligible prescription fills, to approximate the episode dura-
tions. Prescription eligibility is determined based on pre-
specified assumptions regarding allowable maximum gaps
between prescriptions. Aggregation may or may not account
for overlaps between prescriptions.
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In this study, the duration of each prescription filled was
approximated and compared under three different dosage de-
termination methods: actual prescribed dosage (method A),
one unit per day assumption (method B), and one DDD per
day assumption (method C). Method A provides the reference
method in determining the actual duration of each prescription
dispensed. The duration for each prescription under each of
these approaches is given by:
Method A
Method B
Method C
D ¼ p u
r
D ¼ p u
D ¼ p d
whereD is the duration of a prescription fill, p is the number of
the prescribed packages, u is the number of units of drug per
package, r is the actual prescribed number of units per day,
and d is the number of DDDs per package as recorded in the
PDR.
Under each of the three dosage determination
methods, different sub-methods to account for gaps
and overlaps between prescriptions were evaluated.
The variability in treatment episodes duration was
assessed for allowable gaps of different lengths, specif-
ically 0, 10, 30, 60, 90, and 180 days. Allowing for a
gap of a certain number of days means that two con-
secutive prescriptions will be included in the same treat-
ment episode if the gap between them is less than or
equal to the allowed gap. Two different approaches
were applied to evaluate the impact of overlaps on the
duration of treatment episodes. One approach accounts
for overlapping days between prescriptions by adding
them at the end of the duration of the episode, while
the other ignores any overlapping days. Prescriptions
filled on the same date were handled as overlaps. All
the investigated methods (A, B, and C) assume as
starting time of a treatment episode, the date when in-
dividuals first collect the drug from the pharmacy.
For each included individual, the duration of the first treat-
ment episode was approximated by aggregating days of sup-
ply over all eligible prescriptions while systematically varying
the length of the allowed gap and the handling of overlaps.
The study design gave rise to a total of 36 (3 dosagemethods ×
6 allowable gaps × 2 ways for handling overlaps) alternative
constructions of the first treatment episode for each of the two
included medications. The application of the methods is illus-
trated in Appendix F of the supplementary material via R
scripts used to produce the results.
Descriptive analysis
Box and whisker plots were used to display descriptive statis-
tics (median, 1st, and 3rd quartiles) for the duration of the first
treatment episode for each of the 36 combinations.
Study design and statistical modeling
To assess the impact of misclassification of exposure time
from treatment episode construction, we performed a within
individuals study which allows to compare individuals with
themselves under different exposure definitions. To assess
whether treatment episodes constructed under different as-
sumptions impact the odds of observing the outcome of inter-
est during exposed time, unadjusted conditional logistic re-
gression models were fitted using generalized estimating
equations conditioning at the individual level. Any misclassi-
fication of exposure (relative to the reference method) will
lead to estimates of odds ratios (ORs) different than one.
Conditioning at the individual level, the OR of observing the
outcome as exposed was assessed for different pairs of treat-
ment episodes constructed under different assumptions. In
Appendix F of the supplementary material is illustrated as
the models have been fitted via R scripts. Cluster-robust stan-
dard errors were calculated using the R package drgee
[16–18].
Exposure definition
The exposure was defined as the first treatment episode con-
structed with method A (exposure equal 0) or the alternative
method B or C (exposure equal 1). The contrast was among
treatment episodes constructed based on either method B or C,
with a pre-specified gap and method for handling overlaps,
versus the corresponding treatment episode constructed with
method A (reference method) with the same pre-specified gap
and method for handling overlaps. This gave rise to 192 as-
sessments (24 pairs × 4 outcomes × 2 treatments).
Outcomes
The four outcomes of interest were hospitalization for all
causes, hospitalizations for psychiatric causes, outpatient
visits for all causes, and outpatient visits for psychiatric causes
identified in the NPR via the International Classification of
Diseases 10th revision (ICD-10) codes described in
Appendix B of the supplementary material.
Interpretation of the results
An OR less (or more) than one indicates that the alternative
method B or C would result in an under-estimation (or over-
estimation) of the outcome rate during exposed time relative
to the reference method A. It can be interpreted as a measure
of the impact of exposure time misclassification on measures
of the outcomes of interest and consequently on misclassifi-
cation impact on measures of association between exposure
and outcomes.
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Results
Descriptive statistics
The citalopram cohort included 400,388 individuals who
filled 2,537,045 prescriptions and the mirtazapine cohort in-
cluded 292,136 individuals with 1,482,411 prescriptions filled
during the observation period. The distribution over strengths
for the included filled prescriptions was 632,077 (42.64%) for
15 mg, 723,281 (48.79%) for 30 mg, and 127,053 (8.57%) for
45 mg for mirtazapine, and 481,427 (18.98%) for 10 mg,
1,786,705 (70.42%) for 20 mg, 130,306 (5.14%) for 30 mg,
and 138,607 (5.46%) for 40 mg for citalopram.
Duration of prescriptions
The median number of days of supply for mirtazapine pre-
scriptions based on the actual prescribed dosage (method A)
was approximately 96 days. This was similar to the days of
supply (100 days) based on the one unit per day assumption
(method B), but was nearly two times longer than the median
duration of a prescription (50 days) based on DDDs (method
C), implying a significant misclassification of exposure dura-
tion. For citalopram, the median prescription duration under
methods B and C was nearly identical (100 days and 98 days
respectively) to the days of supply based on the actual pre-
scribed dosage (98 days). However, there were sizable differ-
ences in the interquartile range of the days of supply based on
the DDD, leading to misclassification of exposure by
underestimating exposed time relative to the true distribution.
The distributional characteristics of the durations of prescrip-
tions using different dosage assumptions for mirtazapine and
citalopram users are showed in Fig. 1.
Duration of treatment episodes
Figure 2 shows the distribution of the first treatment episode
duration approximated with methods A, B and C, allowing for
gaps of different lengths, and accounting or not for overlaps,
for both mirtazapine and citalopram users. The top row of Fig.
2 presents distributional characteristics of treatment episode
durations obtained using the actual prescribed dosage (method
A) at different allowed gaps and handling of overlaps. In gen-
eral, at each allowed gap, accounting for overlaps causes the
distribution of the treatment episode duration to be more
skewed to the right, while lower quartiles are rather unaffect-
ed.With respect to gaps, increasing the allowable length of the
gap consistently shifts the distribution of the treatment episode
duration to the right and increases the interquartile range.
These patterns were seen for both medications although they
were more pronounced for citalopram.
The second and third rows of Fig. 2 display the distribu-
tional characteristics of the first treatment episode duration
under methods B and C. At each gap length and overlap han-
dling, they can be contrasted with the distributional character-
istics of the first treatment episode duration obtained using the
actual dosage (method A). For mirtazapine users, employing
the one unit per day assumption (method B) when construct-
ing treatment episodes produces a nearly identical treatment
episode duration distribution as the one produced under the
actual dosage (method A), showing only slight differences in
terms of median length, and first and third quartile (Q1 and
Q3), of the first episode. However, using the one DDD per day
assumption (method C) leads to an underestimation of the
treatment episode duration distribution relative to the one ob-
tained based on the actual dosage (method A). These differ-
ences become smaller as the length of allowable gap between
mirtazapine prescriptions becomes larger. The same patterns
Fig. 1 Distributional characteristics of prescription durations in number of days for mirtazapine and citalopram under different dosage assumptions.
Method A—actual prescribed dosage; method B—one unit per day assumption; method C—one DDD per day assumption
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were observed for citalopram users, with small or no differ-
ences in the treatment episode duration characteristics when
constructed using the actual dosage and the one unit per day
assumption, and an underestimation of exposure when using
the one DDD per day assumption relative to actual dosage.
For eachmedication, detailed values of descriptive statistics of
the duration of the first treatment episode for the 36 alterna-
tives are presented in tables 1 and 2 of Appendix C of the
supplementary material.
Impact of the treatment episode construction
on the odds of observing the outcome
during exposed time
Summary results from the 192 models assessing the odds of
observing an outcome of interest during exposed time con-
structed under either method B or C versus method A and a
given set of pre-specified gaps and methods for handling of
overlaps are reported in Table 1. The results (192 ORs) of
using alternative construction methods for treatment episodes
on the four investigated outcomes are illustrated in tables 4-19
in Appendix D of the supplementary material, and the count of
the ORs greater or less than 1 is reported in Table 1. Each table
in Appendix D has 12 comparisons, which consider 6 differ-
ent lengths for the allowed gap (0, 10, 30, 60, 90, 180), and 2
ways of handling overlaps (accounting or not). Consequently
in each cell of Table 1 are reported the directions of the 12
ORs (which could be OR > 1 or OR < 1) and the respective
count (number of OR > 1 or OR < 1), of each table in
Appendix D.
Table 1 indicates that potential exposure time misclassifica-
tion associated with method B results in higher odds of observ-
ing the outcome during exposed time in 77% (37/48) and 100%
(48/48) of the models for mirtazapine and citalopram respec-
tively. Of the remaining alternative comparisons, 23% (11/48)
for mirtazapine results in lower odds of observing the outcome
during exposed time. On the other hand, approximating treat-
ment episode durations based on the DDD (methods C) reduces
the odds of observing the outcome during exposed time in
100% and 87.5% (42/48) of the models for mirtazapine and
citalopram respectively, while 12.5% (6/48) of the models for
citalopram result in higher odds of observing the outcome dur-
ing exposed time. Table 20 in Appendix E shows the differ-
ences in number of events during each alternative approxima-
tion of a treatment episode duration.
Discussion
The present study sought to assess the impact of assumptions
regarding dosage, allowable gaps, and handling of overlaps,
on treatment episode durations, the impact of exposure time
misclassification on measures of the outcomes of interest dur-
ing exposed time, and consequently on the estimation of the
exposure-outcome associations. The study demonstrated that
relative to the actual prescribed dosage retrievable from the
dose text, alternative assumptions significantly impact treat-
ment episode durations leading to misclassification of the ex-
posure time. The results indicate that this would affect esti-
mates of measures of the outcomes of interest. This study
Fig. 2 Distributional characteristics of the duration of the first episode in
number of days for mirtazapine and citalopram users allowing for gaps of
different lengths (0, 10, 30, 60, 90, 180 days), and accounting or not for
overlaps. In the labels of the x-axes, the number indicates the number of
days of the allowed gap, and +/− indicates respectively accounting or not
for overlaps
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demonstrates the exceptional value of utilizing the actual dos-
age information, as well as the superior value of data registries
that contain such information when assessing exposure-
outcome associations.
Foundational to the construction of treatment episodes is
the calculation of a prescription’s days of supply. The medi-
cations considered in this study, mirtazapine and citalopram
are both once daily medications commonly used at dosages
equal to the available unit strength. We consistently found that
the days of supply at the prescription level under the one unit
per day assumption were similar to the ones derived using the
actual dosage for both medications. For once daily medica-
tions, the days of supply using the DDD will depend on the
degree to which the DDD aligns with the prescribed dose. In
the case of citalopram, we found that the median days of
supply were close to those obtained using the actual dosage.
Albeit the overall distributions of days of supply were skewed
to the left due to the fact that 20% of patients were prescribed a
dose lower than the DDD, thus artificially halving the days of
supply for citalopram for the respective users. For
mirtazapine, the actual dose was equal to the DDD in half of
the prescriptions while a lower dose was seen in approximate-
ly 43% of the prescriptions. Using the DDD in this case results
in significant underestimation of the days of supply and mis-
classification of exposure time.
The above observations have been documented elsewhere
in the literature using other medications. A study [4] using the
Finnish Prescription Register, obtained the actual prescribed
dosage based on unstructured free text format and
subsequently assessed the validity of the one unit per day
versus one DDD per day dosage assumption when calculating
treatment duration of statin prescriptions. The study found that
more than 95% of statin prescriptions were dosed at one unit
per day, but only 10% at one DDD per day. The authors
suggested that the one DDD per day cannot be used to gener-
ate valid days of supply, use or exposure measures. A study
using US Medicaid claims data assessed the concordance of
exposure to treatment using reported days of supply and
DDDs in eight medication groups (statins, metformin, atypical
antipsychotics, warfarin, proton pump inhibitors, angiotensin
converting enzyme-inhibitors, non-steroidal anti-inflammato-
ry drugs, and coxib) [19]. The study reported that the DDD
consistently underestimated the exposure across all drug
groups with the exception for non-steroidal anti-inflammatory
drugs where DDD overestimated exposure duration relative to
the reported days of supply. These findings are consistent with
the fact that, differences between the actual days of supply
from the ones calculated based on the one unit per day or
one DDD per day assumptions depend on the frequency of
dosing, and the degree to which the DDD resembles the actual
prescribed dosage. For once daily medications, an assessment
of the distribution of the prescribed medication strengths and
the DDD could provide significant insights on the potential of
DDD to generate reliable days of supply.
In constructing treatment episodes using the actual pre-
scribed dose, the handling of overlaps has a significant impact
on treatment episode durations. This study showed that not
accounting for overlaps consistently underestimated the
Table 1 Impact of treatment episode construction on the odds of capturing the outcome during exposed time. Frequency of the direction of the ORs
relative to 1
Mirtazapine users Citalopram users
OR Count OR Count
Hospitalization for all causes
Method B versus method A ORs > 1 (OR < 1) 11/12 (1/12) ORs > 1 12/12
Method C versus method A ORs < 1 12/12 ORs < 1 12/12
Hospitalizations for psychiatric causes
Method B versus method A ORs > 1 12/12 ORs > 1 12/12
Method C versus method A ORs < 1 12/12 ORs < 1 12/12
Outpatient visits for all causes
Method B versus method A ORs > 1 (OR < 1) 2/12 (10/12) ORs > 1 12/12
Method C versus method A ORs < 1 12/12 ORs < 1 12/12
Outpatient visits for psychiatric causes
Method B versus method A ORs > 1 12/12 ORs > 1 12/12
Method C versus method A ORs < 1 12/12 ORs < 1 (ORs > 1) 6/12 (6/12)
ORs < 1: the alternative approach (method B or C) underestimates the exposure-outcome association relative to the reference (method A), during the first
treatment episode
ORs > 1→ the alternative approach (method B or C) overestimates the exposure-outcome association relative to the reference (method A), during the
first treatment episode
Method A: actual dosage; method B: one unit of drug per day; method C: one DDD per day
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duration of treatment episodes. When the actual prescribed
dosage, and therefore days of supply, is known, adjusting for
overlaps would eliminate one potential source of measure-
ment error in the treatment episode construction. However, it
is not clear what the approach should be in instances where the
one unit per day or one DDD per day assumptions are used to
calculate the days of supply of a prescription and consequently
the level of overlap. Especially when the method leads to an
overestimation of days of supply, accounting for overlaps will
worsen the impact of the method on the overall treatment
episode duration and misclassification of exposure time.
Allowable gaps between prescriptions may be thought of
as assuming continuous treatment although a patient may not
be 100% adherent to the treatment. Poor compliance “in the
real world” actually leads to a right-skewed distribution of
treatment durations, even though at lower daily doses. This
is the case with antidepressants which are often associated
with poor compliance[1, 13], and therefore during the analy-
ses the assumption of 100% compliance is modified by the
allowance of a gap between end of days of supply and the next
prescription fill. The choice of allowable gap between pre-
scriptions has a significant impact on treatment episode dura-
tions and the approach in this study used a fixed number of
days as gaps. The risk with greater gaps is of constructing
treatment episodes of greater duration by including time that
a patient is not under treatment and thus affecting measures of
outcomes during exposed periods.
These findings are consistent with what is reported in a
study of the impact of gaps and overlaps on the median anti-
depressant treatment episode duration [1, 13]. In general han-
dling of overlaps and longer gaps are associated with in-
creased median treatment episode duration and greater inter-
quartile range especially when gaps are a percentage of days
of supply and when overlaps are accounted for. Similarly, a
study of statin medication use using the Swedish PDR [20]
showed that disregarding overlapping days resulted in esti-
mates of reduced use while increasing the allowed gap from
30 to 60 days resulted in increasing use from 57 to 69%, and
consequently longer treatment episode durations.
Perhaps the most significant contribution of this study was
the assessment of the effect of treatment episode duration,
constructed under alternative dosage assumptions relative to
the actual dosage, on the odds of observing the outcomes of
interest during exposed periods. The modeling approach al-
lows us to infer whether there is a concordance in the odds of
observing an outcome between the actual exposure (model A)
and an alternative treatment episode construction (method B
or C). The results provide stark evidence that in the over-
whelming proportion of cases, both model B and C would
lead to over- or under-estimation of estimates in measures of
frequency of an outcome. This occurs even in instances where
the alternative approaches yield treatment episode durations
that are similar in median to the actual exposure. It is evident
that differences in other distributional characteristics of treat-
ment episode duration adversely affect estimation of such
measures. For example, it was observed that the interquartile
range increased when the allowable gaps were greater and
when accounting for overlaps. Greater interquartile range is
associated with increased spread in treatment episode dura-
tions, which in turn translates to over- or under-estimated
measures of outcome ratios and/or rates. These observations
have been confirmed in an earlier study assessing prevalence
of statin use at a pre-specified point in time. Under different
scenarios of treatment episode construction that vary by the
handling of gaps and overlaps, Mantel-Teeuwisse et al. [21]
showed that the estimates of point prevalence vary by method
used to construct treatment episodes.While this study benefits
of the strength of a within individuals design, which by defi-
nition account for all background factors, using other types of
study designs and statistical approaches, research questions on
the effect of background factors on exposure misclassification
may be of interest for future investigations. In general, relying
on assumptions regarding dosagewhen constructing treatment
episodes entails the potential of misclassification of exposure
time. Misclassification of exposure time due to assumptions
used when constructing treatment episodes will likely have an
adverse impact on measures of medication exposure risk. A
study among Dutch NSAID users [22] compared pre-
specified fixed exposure times to the one implied by quantity
supplied and dosage information assuming full compliance.
The study found that misclassification of exposure resulting
from longer than actual exposure times, resulted in lower in-
cidence rates of peptic ulcer therapy.
Depending on medication characteristics such as the num-
ber of available strengths, dosing frequencies, distribution of
prescribed strengths, but also medication type, adverse effect
profiles and other characteristics, treatment episode durations
may be affected not only by the assumptions used but also by
the treatments involved. In the present study this can be seen
in the differences in the distributional profiles of the treatment
episode duration under method C for mirtazapine and
citalopram relative to the one obtained under the actual dosage
assumption. In such instances the misclassification of expo-
sure time would give rise to misclassification of outcomes by
exposure type. Such differential misclassification of outcomes
would lead to over- or under-estimation of measures of the
exposure-outcome association. This observation was also
highlighted previously by van Staa et al. [22] where it was
recognized that if variation in exposure risk across groups is
not accounted for, then risk comparisons would not be valid.
A study using [23] the Clinical Practice Research Datalink, a
national UK primary care registry, assessed how various de-
cisions in constructing treatment episodes affect estimates of
cardiovascular risk among users of hypoglycemic and gluco-
corticoid medications. The decisions included the use of a
fixed exposure versus recorded prescription duration. The
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study found that the choice of the actual versus the fixed
duration resulted in significantly different hazard ratios.
While the authors attribute the variation in the effect estimate
to the high proportion of missing values of the reported pre-
scription duration, the finding could also be related to misclas-
sification of exposure time associated with the different
choices of treatment episodes.
In summary, the results of the current work show the im-
portance of careful consideration of all information available
when approximating the duration of the exposure of interest.
This is particularly important when prescription registers are
used to make inference on exposure-outcome associations. In
such cases the lack of specific information regarding exposure
(actual drug intake, the intended indication and often the dos-
age prescribed) necessitates the use of assumptions, which
have a bearing on the estimated measures of the outcomes.
In this study, using either the one unit per day or the one DDD
per day assumption led to exposure time misclassification
relative to the actual dosage. While the study contributed sig-
nificant insights on the impact of assumptions on the construc-
tion of treatment episodes, it is not possible to provide an
“optimal” method or general recommendation for the treat-
ment episode construction because this is strongly connected
with the particular therapeutic area, where different medica-
tions require different assumptions on dosage.
Conclusion
We have demonstrated that relative to the actual prescribed
dosage, alternative assumptions as well as different ap-
proaches to handling gaps and overlaps, significantly impact
treatment episode durations, which in turn affects measures of
the outcomes of interest during exposed time. This exposure
time misclassification may give rise to misclassification of
outcomes by exposure type and therefore lead to over- or
under-estimation of measures of the exposure-outcome asso-
ciations. Therefore, it is recommended, to utilize actual dosage
information when constructing treatment episodes. When true
dosage is not available, we recommend sensitivity analyses of
treatment episode construction, in order to assess the robust-
ness of the derived measures of associations between out-
comes and exposure under different assumptions. The study
provides results which have a consistent clinical relevance. In
particular when conducting post authorization studies on the
safety or effectiveness of a treatment using observational data
from prescription registers, avoiding exposure misclassifica-
tion is crucial. We have showed that a non-accurate construc-
tion of exposure time may lead to errors on outcome detection
during exposed time, and consequently affect conclusions on
safety or efficacy profile of a treatment.
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